Latest Pharma and Biotech News
Biotechnology
26 November 2024 US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement.
Today's issue
Refine Search
Biotechnology
Privately-held Australian biotech Cartherics has granted Shunxi Holding Group a license to develop, manufacture and commercialize its autologous CAR-T cell product, CTH-004, for multiple solid tumors including ovarian cancer in Greater China. 28 April 2023
Biotechnology
Australian medicines regulator the Therapeutic Goods Administration (TGA) has approved the application from the local subsidiary of US mRNA vaccines specialist Moderna to transition its COVID-19 vaccine, Spikevax (elasomeran), from provisional to full registration. 28 April 2023
Biotechnology
As with many biopharma firms, Gilead Sciences reported a drop in first-quarter revenue this year due to a decline in sales of a COVID-19 treatment. 28 April 2023
Pharmaceutical
The European medicines Agency’s (EMA) human medicines committee (CHMP) recommended six novel medicines for approval at its April 2023 meeting. 28 April 2023
Biotechnology
US muscle biology specialist Cytokinetics is set to wind down the Phase III trial of its amyotrophic lateral sclerosis (ALS) pipeline drug, reldesemtiv, as there is no evidence of an effect compared to placebo on primary or secondary endpoints. 28 April 2023
Biotechnology
Californian biopharmaceutical firm Amgen as reported a 2% drop in revenues in the first quarter, to $6.1 billion, a reflection of falling sales from COVID-19 therapeutics. 28 April 2023
Biotechnology
Nektar Therapeutics has announced that it will be regaining the full rights to rezpegaldesleukin (REZPEG; NKTR-358) from Eli Lilly (NYSE: LLY) which concludes the two companies’ collaboration that begun in 2017. 28 April 2023
Pharmaceutical
Eli Lilly’s tirzepatide moved a step closer to seizing a share of the obesity market on Thursday, when the US drugmaker’s shares were up by more than 2% in early trading. 27 April 2023
Pharmaceutical
When it comes to getting a novel foreign-made treatment into China as quickly as possible, companies should also look into the local policies in some high-profile special zones. 27 April 2023
Pharmaceutical
Eli Lilly’s gains in the stock market on Thursday were likely mostly down to positive data on investigative drug tirzepatide in obesity. 27 April 2023
Pharmaceutical
US pharma major AbbVie today reported earnings for first quarter of 2023 that were lower than the same period of last year but came in line with the Wall Street estimates. 27 April 2023
Pharmaceutical
Bristol Myers Squibb has reported first-quarter 2023 revenue of $11.34 billion, a 3% decline on the same period of 2022. 27 April 2023
Pharmaceutical
Swedish Orphan Biovitrum, also known as Sobi, today released financial results for the first quarter of 2023, showing that total revenues were up 6% year-on-year at 5,239 million Swedish kronor ($508.6 million), but down 2% at constant exchange rates (CER). 27 April 2023
Pharmaceutical
A fall in sales of the COVID-19 treatment Lagevrio (molnupiravir) led revenue at Merck & Co to fall by 9% to $14.49 billion in the first quarter of 2023. 27 April 2023
Pharmaceutical
UK pharma major AstraZeneca this morning reported first-quarter 2023 financial results, with total revenues of $10.879 billion, a decline of 4% (1% increase at constant exchange rates) impacted by lower sales of COVID-19 medicines. 27 April 2023
Biotechnology
Cambridge, USA-based Orbital Therapeutics, which debuted last September with the vision of enhancing global health by unleashing the full potential of RNA medicines to treat human disease in ways that were not previously possible, has now announced the successful closing of a $270 million Series A financing. 27 April 2023
Pharmaceutical
Shares of US drugmaker Vertex Pharmaceuticals closed down 2.6% at $323.30 yesterday, despite the firm announcing that the US Food and Drug Administration (FDA) has approved the expanded use of Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor). 27 April 2023
Biosimilars
German generics drugmaker STADA Arzneimittel and Sweden’s Xbrane Biopharma are working together on a supply agreement for Ximluci (ranibizumab). 27 April 2023
Pharmaceutical
Outperforming many analysts’ expectations, French drugmaker Sanofi has posted revenues of 10.2 billion euros ($11.3 billion) for the first quarter 2023. 27 April 2023
Biotechnology
In a first, more adult patients living with certain forms of blood cancer will now be able to access CAR T-cell therapy on the UK’s National Health Service (NHS). 27 April 2023
All news
Biotechnology
US companies Arrowhead Pharmaceuticals and Sarepta Therapeutics have announced a global licensing and collaboration agreement. 26 November 2024
Pharmaceutical
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today announced that Dr Thomas Schinecker, chief executive (CEO) of Swiss pharma giant Roche (ROG: SIX), will take up the post as president of the trade association effective January 1, 2025. 26 November 2024
Pharmaceutical
US central nervous system (CNS) disorders specialist Axsome Therapeutics today released encouraging late-stage results for its narcolepsy candidate AXS-12 (reboxetine), sending its shares edging up 2.6% to $100.00 in pre-market activity. 26 November 2024
Biotechnology
Clinical-stage US CAR-T therapies developer Poseida Therapeutics saw its shares skyrocket 227% to $9.36 pre-market today, on the news of a proposed takeover by Swiss pharma giant Roche. 26 November 2024
Pharmaceutical
Shares in US biotech major Amgen were 11% lower early on Tuesday. 26 November 2024
Biotechnology
Replimune, a clinical-stage biotech focused on oncolytic immunotherapies, has announced plans to raise $125 million through a public offering. 26 November 2024
Biotechnology
Chinese gene therapy firm Kanglin Biotechnology has completed a $20 million series A financing round, with the money earmarked for KL003, an innovative treatment for blood disorders. 26 November 2024
Biotechnology
BRL Medicine, a Shanghai-based biotechnology company specializing in cell and gene therapies, has raised nearly 200 million yuan ($27 million) in a series B+ round led by CSPC Fund. 26 November 2024
Biotechnology
Italian oncology focused biotech Nerviano Medical Sciences yesterday announced that it has successfully negotiated with Germany’s Merck KGaA to buy back the full world-wide rights of NMS 293 (also known as NMS-03305293). 26 November 2024
Biotechnology
South African-Australian private equity firm LeapFrog Investments has announced the close of its fourth fund (Fund IV), with commitments and designated co-investments totalling $1.02 billion. 26 November 2024
Biotechnology
Pyxis Oncology has announced encouraging preliminary data from a Phase I trial of PYX-201, its lead antibody-drug conjugate (ADC), in solid tumors. 26 November 2024
Biotechnology
The Phase III SKYSCRAPER-01 trial has missed its primary endpoint, Swiss cancer giant Roche has reported. 26 November 2024
Pharmaceutical
Spanish HIV focused immunotherapies company AELIX Therapeutics, a spin-off of IrisCaixa, has announced the acquisition of its investigational assets related to the HTI therapeutic HIV vaccine by US antiviral specialist Gilead Sciences. 26 November 2024
Biotechnology
US biopharma Biohaven has provided an update regarding the taldefgrobep alfa development programs in spinal muscular atrophy (SMA) and obesity. 25 November 2024
Biotechnology
Cassava Sciences, a US biotech developing a novel, investigational treatment for Alzheimer’s disease (AD) dementia, was trading 83% lower at midday on Thursday. 25 November 2024
Pharmaceutical
Positive top-line results from the Phase III ZENITH study evaluating Winrevair (sotatercept-csrk) in adults with pulmonary arterial hypertension (PAH, WHO Group 1) functional class (FC) III or IV at high risk of mortality, were released today by US pharma giant Merck & Co. 25 November 2024
Biotechnology
The US Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for belantamab mafodotin in combinations with bortezomib plus dexamethasone (BorDex [BVd]) and pomalidomide plus dexamethasone (PomDex [BPd]) for multiple myeloma patients who have received at least one prior line of therapy. 25 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has approved Imkeldi (imatinib) oral solution, the first oral liquid form of imatinib to treat certain forms of leukemia and other cancers, from privately-held US-Ireland-based pharmaceutical company Shorla Oncology. 25 November 2024
Pharmaceutical
Specialist pre-clinical contract research organization (CRO) and ion channel screening company Metrion Biosciences has announced the appointment of Lee Patterson as its new chief executive. 25 November 2024
Pharmaceutical
Levothyroxine, a widely prescribed treatment for hypothyroidism, may contribute to bone loss in older adults, according to new research presented at the Radiological Society of North America’s (RSNA) annual meeting. 25 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze